H-100, a topically applied gel composed of nicardipine, superoxide dismutase and emu oil, shows promise for the treatment of Peyronie's disease, say researchers. In the study, 11 patients received H-100 for 3 months and 11 patients received placebo for 3 months. All 22 patients then received H-100 for an additional 3 months. H-100 treatment was associated with increased mean stretched penile length, reduced mean penile curvature and reduced mean pain level. Placebo was only associated with a small improvement in mean stretched penile length. Improvements in all parameters were seen in patients who switched from placebo to H-100 treatment.